All News
Increasing Corticosteroid Use in Non-Hospitalized COVID-19
JAMA reports that despite NIH recommendations (that corticosteroids only be used in hospitalized COVID-19 patients), nonhospitalized COVID infected patients were oftent prescribed systemic corticosteroids.
Read Article
Is Gout Protective Against Dementia?
d
MedPage Today
People with gout appeared less likely to develop dementia than age- and sex-matched peers, a database study from Korea found.
Read Article
Long COVID Manifestations
d
MMWR
The acute consequences of a SARS-CoV-2 infection may be bothersome or devastating, but the long-term consequences may lead to so-called "long COVID" syndrome. Long COVID appears to affect up to 20% of those who survive COVID-19 infection.
Read Article
To TDM or Not in Rheumatology?
Therapeutic Drug Monitoring (TDM), especially for biologic therapies, has become a standard in gastroenterology, but shunned by most rheumatologists.
Read Article
🆒 Current indications for #biologics, in inflammatory rheumatic diseases 🔎 such as rheumatoid #arthritis, axSPA, PsA etc... A useful checklist ✅ to keep in the pocket prepared with
@DocFelten #Rheumatology #EULAR2022 https://t.co/cfc4VaF6GZ
Laurent ARNAUD Lupusreference ( View Tweet)
A Roadmap for Investigating Preclinical Autoimmunity Using Patient-Oriented and Epidemiologic Study Designs: Example of Rheumatoid Arthritis - a comprehensive overview of studies of preclinical RA and risk of RA https://t.co/DKbDXkvFyQ
Dr. John Cush RheumNow ( View Tweet)
@ERheumat @mukes_dr @drMsayan @vikasagrIMMUNO @DurgaPrasannaM1 @LatikaGupta_ @Janetbirdope @AshimaMakol @sclerodermaUM @PanktiMehta24 @ACR_Journals Sclerotylosis… Huriez Syndrome?
Triad of 1) sclerodactyly 2) palmoplantar keratoderma 3) nail changes. High susceptibility of early onset squamous cell cancer of affected areas
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Study of 100 pts w/ gouty arthritis, 51% had hypertension, nearly half insufficiently controlled. Undiagnosed HTN was seen in 18%. Gouty pts w/ HTN frequently (92%) had serum uric acid levels above the target https://t.co/jc0UGyrK2B https://t.co/kDD2KfQd3K
Links:
Dr. John Cush RheumNow ( View Tweet)
Can SGLT2 Inhibitors Be Protective in Lupus and Vasculitis?
SGLT2 inhibitors are all the buzz in the renal world with reports of a renal protective and mortality lowering effects
https://t.co/9mzE06K9uO
#MedEd https://t.co/dVgOtCSHFU
Links:
Dr. John Cush RheumNow ( View Tweet)
86 #SLE pts w/ pulmonary embolism (age 38 yrs; avg lupus duration 46.5 mos) found 20% died; 1 yr (83.4%) & 3-year survival (79.4%). Mortality Predictors = Thrombocytopenia & lymphocytopenia. HCQ & anticoagulation were protective https://t.co/ot7H6LeLmu https://t.co/WdPgvOF8jJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Amitriptyline and FDA Treatments for Fibromyalgia #MedEd
https://t.co/9PylojjL4S https://t.co/TxErjtU4eE
Links:
Dr. John Cush RheumNow ( View Tweet)
It's our 8th year covering this important meeting! Join us June 1 - 4 for key opinion leader perspectives, clinical trial highlights and more, as we cover #EULAR2022. https://t.co/eHziBN3TWk
Dr. John Cush RheumNow ( View Tweet)
Congratulations to Dr. Alexis Ogdie for being appointed Director of the Center for Clinical Epidemiology & Biostatistics at the Perelman School of Medicine at U Penn. CCEB is an interdisciplinary prg focused on research and educational thhttps://bit.ly/39N96Ok https://t.co/RlRCuYO7VV
Dr. John Cush RheumNow ( View Tweet)
May 2022 EMA meeting the CHMP recommended new indications for Cosentyx (juvenile PsA, Enthesitis-related arthritis), Olumiant (alopecia areata), Rinvoq (ulcerative colitis) and Xeljanz (ankylosing spondylitis). EMA approval pending https://t.co/KauDY6e8zS https://t.co/mmv4G9jHI7
Links:
Dr. John Cush RheumNow ( View Tweet)
NSAID use is not associated with increased COVID-19 severity, all-cause mortality, invasive ventilation, AKI, or ECMO in COVID-19 inpatients. 38-center retrospective cohort propensity matched of EHR data from the National COVID Cohort Collaborative. https://t.co/u6Id4WnLPT
Links:
Dr. John Cush RheumNow ( View Tweet)
Disease modification has been defined in multiple disease areas but no widely accepted definition exists for SLE. Learn about the benefits & why there’s a need to consider therapies that modify the immunologic mechanisms of SLE. Sponsored by GSK USMA https://t.co/012Wk0d9Uu https://t.co/yteiuKDLLL
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 282 inflammatory arthritis (IA) pts Rx with TNFi, 11 (3/9%) had neutralizing anti-drug Abs (nADAb). nADAb+ was more likely in smokders; such had significantly worse Dz activity, physical function, & inflammatory markers https://t.co/TnEKGpTQ85 https://t.co/I0hv5X35P1
Links:
Dr. John Cush RheumNow ( View Tweet)
""It's easy to make a buck. It's a lot tougher to make a difference." - Tom Brokaw
Dr. John Cush RheumNow ( View Tweet)
NEJM Case: 73 yoM w/ 1 mo hx of fatigue & diffuse bone pain, pancytopenia (no abd pain, neuro Sx of HSM). WBC 1.7, Hgb 5.9, P111k, MRI shows AVN femura & Humerus. Bone marrow bx revealed macrophages w/ “wrinkled tissue paper” https://t.co/raObXpTHBr https://t.co/U6nQnPKtqI
Links:
Dr. John Cush RheumNow ( View Tweet)
Medscapes list of Best & Worst States to Practice
Best 5: 1) Idaho 2) Georgia 3) S. Dakota 4) Texas 5) Indiana
Worst 5: 1)Maine 2)Maryland 3)W.Virginia 4)Rhode Island 5)Wash DC
https://t.co/4faJiy9l3D https://t.co/k9WKqo8pah
Links:
Dr. John Cush RheumNow ( View Tweet)
